興科蓉醫藥：2024中期報告.pdf

1、2024INTERIM REPORT中期報告Sinco Pharmaceuticals Holdings Limited 兴科蓉医药控股有限公司2024 Interim Report 中期報告Contents目錄2Corporate Information公司資料4Financial Highlights財務摘要6Corporate Profile公司簡介7Management Discussion and Analysis管理層討論及分析24Other Information其他資料32Independent Review Report獨立審閱報告34Interim Condensed Co

2、nsolidated Statement of Profit or Loss and Other Comprehensive Income中期簡明綜合損益及其他全面收益表35Interim Condensed Consolidated Statement of Financial Position中期簡明綜合財務狀況表37Interim Condensed Consolidated Statement of Changes in Equity中期簡明綜合權益變動表38Interim Condensed Consolidated Statement of Cash Flows中期簡明綜合現金流量

3、表40Notes to Interim Condensed Financial Information中期簡明財務資料附註66Definitions釋義Corporate Information公司資料2Sinco Pharmaceuticals Holdings Limited Interim Report 2024BOARD OF DIRECTORSExecutive DirectorsMr.Huang Xiangbin(Chairman)Mr.Lei ShifengMr.Huang Zhijian(appointed with effect from 26 March 2024)Inde

4、pendent Non-executive DirectorsMr.Lau Ying KitMr.Liu WenfangMr.Wang QingMr.Bai ZhizhongAUDIT COMMITTEEMr.Lau Ying Kit(Chairman)Mr.Liu WenfangMr.Wang QingMr.Bai ZhizhongREMUNERATION COMMITTEEMr.Wang Qing(Chairman)Mr.Liu WenfangMr.Bai ZhizhongMr.Lei ShifengNOMINATION COMMITTEEMr.Huang Xiangbin(Chairma

5、n)Mr.Liu WenfangMr.Lau Ying KitINTERNAL CONTROL AND CORPORATE GOVERNANCE COMMITTEEMr.Lau Ying Kit(Chairman)Mr.Wang QingMr.Liu WenfangMr.Bai ZhizhongMr.Lei ShifengAUTHORISED REPRESENTATIVESMr.Huang XiangbinMs.Peng Yunlu(appointed with effect from 26 March 2024)Mr.Li Kin Wai(resigned with effect from

6、26 March 2024)COMPANY SECRETARIESMs.Peng YunluMr.Li Kin Wai(resigned with effect from 26 March 2024)REGISTERED OFFICEPO Box 309Ugland HouseGrand Cayman,KY1-1104Cayman Islands董事會執行董事黃祥彬先生（主席）雷世鋒先生黄智健先生（於2024年3月26日獲委任）獨立非執行董事劉英傑先生劉文芳先生汪晴先生白志中先生審核委員會劉英傑先生（主席）劉文芳先生汪晴先生白志中先生薪酬委員會汪晴先生（主席）劉文芳先生白志中先生雷世鋒先生提名